Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease

Launched by DIAKONHJEMMET HOSPITAL · Apr 29, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how glucocorticoids, a type of medication often used to treat inflammatory joint diseases, affect bone turnover markers (BTMs) in patients. BTMs are substances in the blood that can help doctors understand how well bones are being formed or broken down. The study aims to gather more information on how glucocorticoid treatment changes these markers during and after treatment, especially since these medications can increase the risk of osteoporosis and fractures. Understanding these changes can help improve patient care and reduce potential side effects.

To be eligible for this trial, participants must have a diagnosis of an inflammatory rheumatic joint disease and either need to start a specific treatment or be receiving stable treatment that includes glucocorticoids. However, people with known osteoporosis, those who have had fractures in the past year, or those on certain other treatments are not eligible. If you choose to participate, you will be monitored to see how your BTMs change throughout the study. This research is important because it can lead to better management of osteoporosis risks in patients undergoing glucocorticoid treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • diagnosis of inflammatory rheumatic joint disease
• • indication of disease modifying treatment initiation with or without glucocorticoids OR
• • stable DMARD treatment with parenteral glucocorticoid injection
• Exclusion Criteria:
• • known osteoporosis or osteoporosis treatment
• • women during the transitory phase
• • oestrogen treatment
• • any fracture within the last year
• • chronic glucocorticoid treatment
• • glucocorticoid treatment within the last year prior to inclusion
• • active cancer
• • kidney failure